Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-11-23 Sale |
2022-11-28 7:30 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $30.48 | $609,600 | 2,107,225 (Indirect Direct) |
View |
| 2022-11-01 Sale |
2022-11-03 5:37 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $30.27 | $605,463 | 2,127,225 (Indirect Direct) |
View |
| 2022-09-29 Sale |
2022-10-03 4:05 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
10,838 | $702.24 | $7,610,844 | 12,921 (Direct) |
View |
| 2022-09-28 Sale |
2022-09-30 4:50 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $30.82 | $616,304 | 2,147,225 (Indirect Direct) |
View |
| 2022-08-23 Sale |
2022-08-25 6:11 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $31.61 | $632,282 | 2,167,225 (Indirect Direct) |
View |
| 2022-07-25 Sale |
2022-07-27 6:49 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $35.61 | $712,110 | 2,187,225 (Indirect Direct) |
View |
| 2022-03-23 Sale(A) |
2022-06-28 3:07 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $33.83 | $676,583 | 2,261,239 (Indirect Direct) |
View |
| 2022-06-23 Sale |
2022-06-27 8:54 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
60,000 | $30.72 | $1,843,045 | 2,207,225 (Indirect Direct) |
View |
| 2022-03-23 Sale |
2022-03-25 5:57 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
20,000 | $33.83 | $676,583 | 2,261,239 (Indirect Direct) |
View |
| 2022-03-21 Sale |
2022-03-23 4:01 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
7,439 | $690 | $5,132,910 | 2,269 (Direct) |
View |
| 2022-03-16 Sale |
2022-03-18 4:05 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
12,191 | $678.21 | $8,268,075 | 2,269 (Direct) |
View |
| 2021-12-28 Sale |
2021-12-30 9:59 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
63,131 | $44.43 | $2,805,197 | 2,323,218 (Indirect Direct) |
View |
| 2021-12-09 Sale |
2021-12-10 5:41 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
3,784 | $665 | $2,516,360 | 2,078 (Direct) |
View |
| 2021-09-13 Sale |
2021-09-15 4:02 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
12,750 | $641.71 | $8,181,827 | 14,828 (Direct) |
View |
| 2021-06-07 Sale |
2021-06-08 5:10 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
94,378 | $70.35 | $6,639,523 | 2,552,232 (Direct) |
View |
| 2021-05-21 Sale |
2021-05-24 8:05 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
46,763 | $60.11 | $2,811,048 | 2,542,296 (Direct) |
View |
| 2021-05-03 Sale |
2021-05-05 4:14 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
3,237 | $60.11 | $194,589 | 2,589,059 (Direct) |
View |
| 2021-04-01 Sale |
2021-04-05 4:10 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
50,000 | $56.62 | $2,831,071 | 2,592,296 (Direct) |
View |
| 2021-03-01 Sale |
2021-03-03 4:20 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
100,000 | $66.22 | $6,622,207 | 2,642,296 (Direct) |
View |
| 2020-06-16 Sale |
2020-06-18 9:41 pm |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
400,000 | $26.1 | $10,440,000 | 2,739,043 (Direct) |
View |
| 2020-05-06 Sale |
2020-05-08 4:03 pm |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
15,000 | $563.97 | $8,459,496 | 1,830 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-05-31 Option Award |
2024-06-04 6:31 pm |
N/A 2034-05-31 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
23,868 | $0 | 2,135,309 (Direct) |
View |
| 2023-06-01 Option Award |
2023-06-05 6:06 pm |
N/A 2033-06-01 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
16,865 | $0 | 2,124,090 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 4:16 pm |
N/A 2033-01-03 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
2,094 | $0 | 4,363 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 4:16 pm |
N/A 2033-01-03 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
2,094 | $0 | 4,363 (Direct) |
View |
| 2022-09-29 Exercise |
2022-10-03 4:05 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
10,838 | $413.33 | 12,921 (Direct) |
View |
| 2022-09-29 Exercise |
2022-10-03 4:05 pm |
N/A 2025-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
10,838 | $0 | 12,921 (Direct) |
View |
| 2022-06-02 Option Award |
2022-06-06 8:09 pm |
N/A 2032-06-02 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
23,945 | $0 | 2,285,184 (Direct) |
View |
| 2022-03-21 Exercise |
2022-03-23 4:01 pm |
N/A 2028-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
7,439 | $0 | 2,269 (Direct) |
View |
| 2022-03-21 Exercise |
2022-03-23 4:01 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
7,439 | $380.95 | 2,269 (Direct) |
View |
| 2022-03-17 Exercise |
2022-03-18 4:05 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
7,830 | $376.69 | 2,269 (Direct) |
View |
| 2022-03-16 Exercise |
2022-03-18 4:05 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
4,361 | $374.12 | 2,269 (Direct) |
View |
| 2022-03-16 Exercise |
2022-03-18 4:05 pm |
N/A 2030-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
12,191 | $0 | 2,269 (Direct) |
View |
Ownership |
2022-02-17 8:25 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
0 | $0 | 2,281,239 (Indirect) |
View |
| 2021-12-13 Ownership |
2022-02-17 8:25 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
200,000 | $0 | 2,281,239 (Direct) |
View |
| 2022-01-03 Option Award |
2022-01-05 4:23 pm |
N/A 2032-01-03 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
2,898 | $0 | 4,976 (Direct) |
View |
| 2021-10-04 Gift |
2021-12-30 9:59 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
400,000 | $0 | 2,323,218 (Direct) |
View |
| 2021-12-09 Exercise |
2021-12-10 5:41 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
3,784 | $371.4 | 2,078 (Direct) |
View |
| 2021-12-09 Exercise |
2021-12-10 5:41 pm |
N/A 2029-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
3,784 | $0 | 2,078 (Direct) |
View |
| 2021-09-13 Exercise |
2021-09-15 4:02 pm |
N/A 2024-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
12,750 | $0 | 14,828 (Direct) |
View |
| 2021-09-13 Exercise |
2021-09-15 4:02 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
4,250 | $273.67 | 14,828 (Direct) |
View |
| 2021-06-07 Exercise |
2021-06-08 5:10 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
27,830 | $18.92 | 2,552,232 (Direct) |
View |
| 2021-06-07 Exercise |
2021-06-08 5:10 pm |
N/A 2027-12-07 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
94,378 | $0 | 2,552,232 (Direct) |
View |
| 2021-06-07 Exercise |
2021-06-08 5:10 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
39,303 | $18 | 2,552,232 (Direct) |
View |
| 2021-06-07 Exercise |
2021-06-08 5:10 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
27,245 | $19.5 | 2,552,232 (Direct) |
View |
| 2021-06-02 Option Award |
2021-06-04 6:37 pm |
N/A 2031-06-02 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
8,296 | $0 | 2,550,592 (Direct) |
View |
| 2021-01-04 Option Award |
2021-01-05 4:11 pm |
N/A 2031-01-04 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
3,861 | $0 | 5,691 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 6:00 pm |
N/A 2030-06-02 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
18,436 | $0 | 18,436 (Direct) |
View |
| 2020-05-06 Exercise |
2020-05-08 4:03 pm |
N/A N/A |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
15,000 | $177.82 | 1,830 (Direct) |
View |
| 2020-05-06 Exercise |
2020-05-08 4:03 pm |
N/A 2023-01-02 |
REGENERON PHARMACEUTICALS INC. | REGN | Tessier-Lavigne Marc Director |
15,000 | $0 | 1,830 (Direct) |
View |